Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Triple-Negative Breast Cancer
Non Small Cell Lung Cancer
Renal Cell Carcinoma
Mesothelioma
Fumarate Hydratase (FH)-Deficient Tumors
Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)
Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors
Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations
Tumors Harboring Amplifications in the cMyc Gene

Interventions

DRUG: CB-839
DRUG: Pac-CB
DRUG: CBE
DRUG: CB-Erl
DRUG: CBD
DRUG: CB-Cabo

Sponsor

Calithera Biosciences, Inc